COMPANY
Acelot
Our lead program, ACE-2223, is a small molecule designed to specifically target aggregated TDP-43 and restore its function, which is central to the pathology of progressive neurological disorders like amyotrophic lateral sclerosis (ALS) and FTLD. From company website Source · Oct 12, 2026